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ABSTRACT
Objective: To describe and correlate neurotoxicity indicators in long-term primary CNS lymphoma
(PCNSL) survivors who were treated with high-dose methotrexate–based regimens with or with-
out whole-brain radiotherapy (WBRT).
Methods: Eighty PCNSL survivors from 4 treatment groups (1 with WBRT and 3 without WBRT)
who were a minimum of 2 years after diagnosis and in complete remission underwent prospective
neuropsychological, quality-of-life (QOL), and brain MRI evaluation. Clinical characteristics were
compared among treatments by using the x2 test and analysis of variance. The association among
neuroimaging, neuropsychological, and QOL outcomes was assessed by using the Pearson cor-
relation coefficient.
Results: The median interval from diagnosis to evaluation was 5.5 years (minimum, 2 years; max-
imum, 26 years). Survivors treated with WBRT had lower mean scores in attention/executive
function (p 5 0.0011), motor skills (p 5 0.0023), and neuropsychological composite score (p 5
0.0051) compared with those treated without WBRT. Verbal memory was better in survivors with
longer intervals from diagnosis to evaluation (p 5 0.0045). On brain imaging, mean areas of total
T2 abnormalities were different among treatments (p 5 0.0006). Total T2 abnormalities after
WBRT were more than twice the mean of any non-WBRT group and were associated with poorer
neuropsychological and QOL outcomes.
Conclusions: Our results suggest that in patients treated for PCNSL achieving complete remis-
sion and surviving at least 2 years, the addition of WBRT to methotrexate-based chemotherapy
increases the risk of treatment-related neurotoxicity. Verbal memory may improve over time.
Classification of evidence: This study provides Class III evidence that in patients treated for PCNSL
achieving complete remission and surviving at least 2 years, the addition of WBRT to methotrexate-
based chemotherapy increases the risk of treatment-related neurotoxicity. Neurology 2013;81:84–92
GLOSSARY
ASCT 5 autologous stem cell transplantation; BBBD 5 blood–brain barrier disruption; CI 5 confidence interval; EORTC 5
European Organization for Research and Treatment of Cancer;MR5magnetic resonance; PCNSL5 primary CNS lymphoma;
QLQ-C30 5 QOL Questionnaire–30; QOL 5 quality of life; WBRT 5 whole-brain radiotherapy.
High-dose methotrexate is the most widely used drug for primary CNS lymphoma (PCNSL). In
combination with whole-brain radiotherapy (WBRT), high-dose methotrexate improved survival
rates over WBRT alone. However, delayed treatment-related neurotoxicity emerged as a significant
disabling complication of the combined treatment.1–9 Single-drug and multidrug high-dose meth-
otrexate–based regimens without WBRT have been used in an effort to increase survival while
avoiding the risk of delayed neurotoxicity.10–15 In patients older than 60 years treated with WBRT,
virtually all long-term survivors develop this complication. In patients younger than 60 years,
neurotoxicity rates ranging from 26% to 63% have been reported.2,6 However, the true risk of
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this complication has likely been underesti-
mated because formal psychometric evaluations
are not routinely performed.1,3,13,16
Patients with treatment-related neurotoxic-
ity often demonstrate MRI abnormalities,
which appear to correlate with cognitive dys-
function after combined therapy6,8,17 but may
not correlate with cognitive decline after meth-
otrexate-based therapy alone.10,11,18 Although
neuropsychological and neuroimaging out-
comes have been identified as indicators of neu-
rotoxicity, these indicators have been evaluated
in a standardized fashion in only a few relatively
small studies.6–8,10,11,14,17–19 As a result, a test
battery evaluating cognition and quality of life
(QOL) was developed by the International
PCNSL Collaborative Group investigators
and recommended for prospective trials.7 The
purpose of this multinational observational
study was to describe and correlate neuropsy-
chological, QOL, and neuroimaging outcomes
in long-term PCNSL survivors.
METHODS Participants. The primary research question was
to investigate whether there were differences in neuropsycholog-
ical, QOL, and neuroimaging outcomes in long-term PCNSL
survivors in complete remission who were treated with high-dose
methotrexate–based chemotherapy with or without WBRT
(Class III evidence). Investigators at 3 institutions in Germany
and 1 in the United States participated. Eligible patients were
a minimum of 2 years after histologic diagnosis of PCNSL and
must have attained complete disease remission after treatment.
Disease remission was required to assess the impact of neurotox-
icity without the confounding presence of infiltrative and often
multifocal CNS disease.
The investigators in Germany identified 55 eligible patients
with PCNSL from an estimated 253 patients with PCNSL who
had been treated with high-dose methotrexate–based chemother-
apy with or without WBRT, or high-dose methotrexate followed
by chemotherapy and autologous stem cell transplantation
(ASCT) with or without WBRT. All 55 patients were enrolled
and underwent neuropsychological evaluation. The investigators
at the US institution identified 25 eligible patients from an esti-
mated 112 patients treated with high-dose methotrexate–based
chemotherapy (intra-arterial) in conjunction with osmotic blood–
brain barrier disruption (BBBD) without WBRT. All 25 patients
underwent neuropsychological evaluation. Determination of
patient eligibility, enrollment, and data collection occurred
between February 2009 and February 2011.
Standard protocol approvals, registrations, and patient
consents. The study (NCT00710151) was approved by the
human investigations or ethics committee at each institution
and was conducted in accordance with the Declaration of Helsin-
ki. Eligible survivors provided written informed consent as
required by institutional guidelines.
Treatment characteristics. All patients (n 5 80) were treated
with high-dose methotrexate–based chemotherapy as initial
treatment (appendix e-1 and table e-1 on the Neurology® Web site
at www.neurology.org). Sixty-five (81%) were treated with regimens
that did not include WBRT, as follows: high-dose methotrexate–
based chemotherapy (n 5 32), high-dose methotrexate (intra-
arterial)–based chemotherapy in conjunction with BBBD (n 5 25),
or high-dose methotrexate followed by high-dose chemotherapy
and ASCT (n 5 8). The median methotrexate dose was 5 g/m2
(minimum, 3 g/m2; maximum, 8 g/m2), and the median number
of methotrexate courses was 6 (minimum, 1; maximum, 24).
Fifteen (19%) of 80 patients received high-dose methotrexate–
based chemotherapy followed by WBRT. Five of the 15 patients
were additionally treated with high-dose chemotherapy and ASCT
before WBRT. The median radiation dose was 45 Gy (minimum,
45 Gy; maximum, 60 Gy), and the median number of fractions
was 30 (minimum, 30; maximum, 50).
Neuropsychological assessment. Each institution assigned
one neuropsychologist or trained research associate to conduct
the neuropsychological evaluation performed in 60–90 minutes
in the ambulatory clinic or in the survivor’s residence or work-
place. A standardized test battery7 designed to evaluate neurotox-
icity in multinational PCNSL trials was used. The tests measure
attention and executive function (Wechsler Adult Intelligence
Scale—III Digit Span subtest [Digits Forward, Digits Back-
ward],20 Trail Making Test Parts A and B,21 and Brief Test of
Attention22), verbal memory (Hopkins Verbal Learning Test–
Revised),23 and motor skills (Grooved Pegboard Test, Dominant
and Nondominant).24
Raw test scores were converted to z scores based on normative
values demographically adjusted to age and, where available, to
age, sex, education, and race/ethnicity.25 A domain score was
obtained by averaging all test z scores in each domain for each
participant. An average z score (composite score) was calculated
by averaging all available domain scores for each participant.
Impaired cognitive performance was defined as a z score $1.5
SD worse than the normative mean.7,8,11,26 Baseline neurocogni-
tive outcomes from subsets of participants were previously
reported.10,11,14,18,27
QOL assessment. Participants completed the European Orga-
nization for Research and Treatment of Cancer (EORTC)
QOL Questionnaire–30 (QLQ-C30) and Brain Cancer Module–
20.28 The EORTC QLQ-C30 measures 5 functional scales and
global QOL. The EORTC QOL Questionnaire Brain Cancer
Module–20 assesses items such as visual disorders, communica-
tion deficit, and future uncertainty. Questionnaires were scored
and analyzed according to the scoring manual.29
Neuroimaging assessment. Neuroimaging was requested
within 90 days of neuropsychological evaluation. In rare instances
when brain MRI was not possible, participants underwent CT
scan. MRI and CT images were evaluated by a single neuroradiol-
ogist (E.D.) blinded to patient information. Axial turbo spin echo
T2-weighted magnetic resonance (MR) or CT images were used to
measure abnormal MR T2 hyperintensities or CT hypodensities
(low attenuation areas) on follow-up images.18 Cross-sectional
areas were calculated from 2 perpendicular linear measurements
that were obtained manually where white matter abnormalities
appeared largest, and then the size of abnormal T2 (MRI) or
low-attenuation (CT) areas was summed.
Statistical analysis. Clinical and demographic characteristics
were summarized by using descriptive statistics and compared
among treatment groups by using the x2 test for categorical var-
iables and analysis of variance for continuous variables. The asso-
ciation between neuroimaging outcomes and neuropsychological
Neurology 81 July 2, 2013 85
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
and QOL outcomes was assessed by using the Pearson correlation
coefficient. To compare differences in neuropsychological, neuro-
imaging, and QOL outcomes, a multivariable linear model was
used while controlling for potential confounding variables in the
baseline.
The following variables were considered for controlling for
confounding in the model: age, Karnofsky Performance Score,
sex, education, intrathecal treatment (yes/no), interval from diag-
nosis to evaluation (years), occupation, and residence (urban/
rural). Univariate association was first assessed between each out-
come and each potential confounding variable by using simple
linear regression, and variables with p , 0.25 were considered
for the multivariable model. Except for treatment group, only
significant variables (p , 0.05) were included in the final model.
Multiple comparisons among different treatment groups were
conducted by using the Tukey Studentized Range Test. Analyses
were performed by using SAS version 9.2 for Windows (SAS
Institute Inc., Cary, NC).
RESULTS Participants. Clinical characteristics at diag-
nosis are summarized overall (n5 80) and according to
treatment group in table 1. The overall median age was
59 years; 35 (44%) were 60 years or older. There was a
significant difference in the proportion of patients older
than 60 years between treatment groups (p5 0.0406).
More patients were older than 60 years in the high-dose
methotrexate without WBRT group compared with
patients treated with BBBD and those treated with
high-dose chemotherapy and ASCT without WBRT.
The overall median Karnofsky Performance Score was
80. There were no differences between groups in mean
Karnofsky Performance Score at diagnosis (p5 0.1395)
or sex (p 5 0.927).
The overall median interval from the date of
PCNSL diagnosis to long-term evaluation was 5.5 years
(minimum, 2 years; maximum, 26 years). Twenty-one
(26%) were evaluated more than 10 years after diagno-
sis. There was a difference between treatment groups in
the interval (p 5 0.0005). Patients treated with high-
dose methotrexate–based chemotherapy with BBBD
had a longer interval (median, 12 years; minimum,
2 years; maximum, 26 years) than the other groups.
Neuropsychological outcomes. The crude mean z scores
for neuropsychological domains, tests, and composite
scores are shown in table 2. The comparison accord-
ing to treatment group is indicated in figure 1A. The
percentage of survivors with impairment in 0, 1, or
multiple cognitive domains according to treatment
group is shown in figure 1B and table e-2. In the
WBRT group, 47% were impaired in multiple do-
mains, compared with 9% in the high-dose metho-
trexate–based group, 16% in the BBBD group, and
13% in the high-dose chemotherapy and ASCT
group. The percentage of survivors impaired in each
domain is shown in table e-2.
In the final model comparing neuropsychological
composite scores among treatments, there were differ-
ences in the interval from diagnosis to evaluation
(p 5 0.0075), treatment group (p 5 0.0237), and
residence (p 5 0.0043). Patients treated with WBRT
had a lower mean composite score and thus poorer
cognitive performance than patients treated with BBBD
(mean difference,20.76; 95% confidence interval [CI],
21.38 to 20.15) and those treated with high-dose
methotrexate–based chemotherapy without WBRT
(mean difference, 20.73; 95% CI, 21.37 to 20.08).
Patients treated with WBRT had a mean score 0.65
points (95% CI, 0.20–1.10; p 5 0.0051) lower than
patients from the 3 non-WBRT groups combined. For
interval from diagnosis to evaluation, the composite
score was 0.04 points (95% CI, 0.01–0.08) higher for
every year increase in the interval. Finally, patients living
rurally had a mean score 0.58 points lower (95% CI,
0.19–0.98) than those living in an urban area.
In the final model for attention/executive function,
an overall difference was found among treatment groups
(p5 0.0104). Patients treated withWBRT had a lower
mean score than patients treated with BBBD (mean
difference, 20.68; 95% CI, 21.27 to 20.10) and all
patients treated with non-WBRT regimens (mean dif-
ference, 20.68; 95% CI, 21.09 to 20.28; p 5
0.0011). Sex (p 5 0.0428) and residence (p 5
0.0176) were also different. Women had a mean score
0.31 points (95% CI, 0.01–0.62) lower than men.
Patients living rurally had a mean score 0.43 points
lower (95% CI, 0.08–0.79) than patients living in an
urban area.
In the final model for motor skills, an overall differ-
ence was found only among treatment groups (p 5
0.0244). Patients treated withWBRT had a lower mean
score than patients treated with BBBD (mean differ-
ence, 21.12; 95% CI, 22.23 to 20.01) and with
high-dose methotrexate–based chemotherapy without
WBRT (mean difference, 21.10; 95% CI, 22.17 to
20.03). Additionally, the WBRT group had a lower
mean score than the other groups combined (mean dif-
ference, 21.24; 95% CI, 22.02 to 20.46; p 5
0.0023).
There was no difference in verbal memory among
treatment groups (p 5 0.1246). However, the verbal
memory domain score corresponded with the interval
from diagnosis to long-term evaluation (p5 0.0045).
With each year increase, there was a 0.07 point (95%
CI, 0.02–0.12) increase in verbal memory score.
There was also a difference in residence (p 5
0.0156). Patients living rurally had a mean score
0.73 points lower (95% CI, 0.15–1.32) than those
living in an urban area.
Neuroimaging outcomes. Neuroimaging data were
obtained from 78 of 80 survivors. The imaging modal-
ity was brain MRI in 76 and brain CT in 2 survivors.
The MRI total T2 areas of abnormalities in square
millimeters (crude mean and SD, respectively) were
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Table 1 Patient demographics and clinical characteristics at diagnosisa





alone (n 5 32)
HDMTX (IA)-based CHT
with BBBD (n 5 25)
HDMTX-based CHT f/b
HDCHT with ASCT (n 5 8)
HDMTX-based CHT f/b
WBRTb (n 5 15)
Sex, n (%)
Male 43 (54) 16 (50) 14 (56) 4 (50) 9 (60)
Female 37 (46) 16 (50) 11 (44) 4 (50) 6 (40)
Age, yc
Median 59 64 49 53 57
Range 10–78 27–78 10–72 39–62 28–75
<60, n (%) 45 (56) 12 (38) 17 (68) 7 (88) 9 (60)
‡60, n (%) 35 (44) 20 (62) 8 (32) 1 (12) 6 (40)
Karnofsky Performance Scored
Median 80 70 80 80 80
Range 20–100 30–100 20–100 70–90 50–100
‡70, n (%) 57 (72) 18 (58) 18 (72) 8 (100) 13 (87)
<70, n (%) 22 (28) 13 (42) 7 (28) 0 (0) 2 (13)
Educational level, n (%)
Completed HS or equivalent 53 (67) 14 (44) 24 (96) 7 (88) 8 (53)
Did not complete HS or equivalent 27 (33) 18 (56) 1 (4) 1 (12) 7 (47)
Occupation, n (%)
Professional/technical 20 (25) 6 (19) 8 (32) 2 (25) 4 (27)
Managerial/clerical 22 (28) 9 (28) 8 (32) 4 (50) 1 (7)
Craftsman/skilled labor 15 (19) 9 (28) 1 (4) 1 (12) 4 (27)
Semiskilled labor 10 (13) 3 (9) 3 (12) 1 (12) 3 (20)
Not in labor force 13 (16) 5 (16) 5 (20) 0 (0) 3 (20)
Residence, n (%)
Urban 61 (76) 26 (81) 18 (72) 6 (75) 11 (73)
Rural 19 (24) 6 (19) 7 (28) 2 (25) 4 (27)
Disease site, n (%)
Brain parenchyma 80 (100) 32 (100) 25 (100) 8 (100) 15 (100)
CSF
Positive for lymphoma cells 2 (3) 1 (3) 1 (4) 0 (0) 0 (0)
Atypical cells 4 (5) 0 (0) 3 (12) 1 (12) 0 (0)
Ocular 2 (3) 1 (3) 1 (4) 0 (0) 0 (0)
Time from diagnosis to long-term evaluation, y
Median 5.5 4.5 12.3 4.5 5.6
Range 2–26 2–15 2–26 2–10 2–12
‡2 to <5 y, n (%) 39 (49) 19 (59) 8 (32) 5 (62) 7 (47)
‡5 to <10 y, n (%) 20 (25) 7 (22) 3 (12) 3 (38) 7 (47)
‡10 to <20 y, n (%) 18 (22) 6 (19) 11 (44) 0 (0) 1 (7)
‡20 y, n (%) 3 (4) 0 (0) 3 (12) 0 (0) 0 (0)
Abbreviations: ASCT 5 autologous stem cell transplantation; BBBD 5 blood-brain barrier disruption; CHT 5 chemotherapy; f/b 5 followed by; HDCHT 5
high-dose chemotherapy; HDMTX 5 high-dose methotrexate; HS 5 high school; IA 5 intra-arterial; WBRT 5 whole-brain radiotherapy.
a Patient demographics and clinical characteristics at diagnosis are listed overall and according to treatment group.
b In 5 of 15 patients, treatment was high-dose methotrexate–based chemotherapy followed by high-dose chemotherapy with autologous stem cell trans-
plantation and whole-brain radiotherapy.
cOne patientwas less than21years old at the time of primaryCNS lymphomadiagnosis. The patientwas10years old at diagnosis and26years old at long-term follow-up.
dKarnofsky Performance Score was missing for 1 patient.
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as follows: overall, 2,679 and 3,160; high-dose metho-
trexate without WBRT, 1,879 and 2,172; BBBD
without WBRT, 2,096 and 3,512; high-dose chemo-
therapy and ASCT without WBRT, 2,049 and
2,704; and high-dose methotrexate followed by
WBRT, 5,604 and 3,085. There was an overall differ-
ence in total T2 (MRI) or low-density CT abnormal-
ities between treatment groups (p5 0.0006; figure 2).
Higher total T2 or low-density abnormalities were
found in the WBRT group compared with other treat-
ments. The mean of total abnormal white matter areas
in the WBRT group was more than twice the mean of
any of the other 3 non-WBRT groups. No other var-
iable was associated with total MR or CT abnormali-
ties in the final model.
For comparison of neuroimaging and neuropsycho-
logical outcomes, patients with more total MRI T2 or
CT abnormalities had poorer neuropsychological perfor-
mance in the attention/executive (r 5 20.38; p 5
0.0006), verbal memory (r 5 20.23; p 5 0.042),
and motor (r 5 20.28; p 5 0.016) domains and in
the neuropsychological composite score (r 5 20.34;
p 5 0.002). Although a similar trend was seen when
neuroimaging with neuropsychological outcomes were
correlated within each group, the correlation was not
significant.
QOL outcomes. Seventy-one (89%) survivors com-
pleted the EORTC QLQ-C30. The overall score for
global QOL (68.2 [mean] and 24.3 [SD]) was posi-
tively associated with the neuropsychological composite
score (r5 0.38; p5 0.0011). A higher composite score
was associated with a higher score in each QLQ-C30
functional scale: physical (r 5 0.38; p 5 0.0011), role
(r 5 0.40; p 5 0.0005), emotional (r 5 0.29; p 5
0.0141), cognitive (r 5 0.30; p 5 0.010), and social
(r 5 0.34; p 5 0.0037). In contrast, more total white
matter abnormalities corresponded with poorer global
QOL (r 5 20.32; p 5 0.0067), and poorer physical
(r 5 20.45; p 5 0.0001), role (r 5 20.38; p 5
0.0012), emotional (r 5 20.30; p 5 0.0112), and
social (r 5 0.41; p 5 0.0005) function. Total white
matter abnormalities and QLQ-C30 cognitive function
scale scores were not associated (r5 0.19; p5 0.1152).
QOL outcomes are shown in figure 3 and table e-3.
DISCUSSION We used a standard neurocognitive
battery and neuroimaging to prospectively assess a
Table 2 Long-term neuropsychological test, domain, and composite z scores of primary CNS lymphoma survivors overall and according to
treatment groupa
Test, domain, and composite
scoreb,c
Total (n 5 80)
HDMTX-based CHT
alone (n 5 32)
HDMTX (IA)-based CHT
with BBBD (n 5 25)
HDMTX-based CHT f/b
HDCHT with ASCT (n 5 8)
HDMTX-based CHT
f/b WBRT (n 5 15)
No. Mean SD No. Mean SD No. Mean SD No. Mean SD No. Mean SD
Attention/executive function
Digits Forward 80 20.08 0.93 32 20.09 0.95 25 0.18 0.78 8 0.15 0.97 15 20.64 0.93
Digits Backward 80 20.11 0.83 32 20.15 0.95 25 20.00 0.63 8 0.14 0.89 15 20.34 0.81
Trail Making Test, A 77 21.22 1.25 32 21.41 1.16 24 20.94 0.95 8 20.24 1.72 13 21.91 1.26
Trail Making Test, B 75 21.06 1.17 31 21.00 1.27 24 20.87 1.03 8 20.75 1.16 12 21.80 1.00
Brief Test of Attention 79 20.50 1.23 32 20.12 1.10 24 20.50 0.95 8 20.92 1.33 15 21.06 1.63
Domain 80 20.59 0.74 32 20.56 0.70 25 20.42 0.50 8 20.32 0.95 15 21.10 0.88
Verbal memory
HVLT-R, learning 80 20.91 1.25 32 20.66 1.04 25 20.94 1.35 8 21.07 1.55 15 21.33 1.31
HVLT-R, delayed 80 20.84 1.30 32 20.49 1.11 25 20.82 1.43 8 21.26 1.49 15 21.40 1.22
Domain 80 20.88 1.21 32 20.57 1.02 25 20.88 1.35 8 21.17 1.47 15 21.36 1.10
Motor skills
Pegboard, dominant 74 21.17 1.34 31 21.02 1.31 24 21.10 1.25 7 20.50 1.66 12 22.12 1.08
Pegboard, nondominant 71 21.24 1.31 30 21.14 1.26 22 20.95 1.37 7 20.88 1.30 12 22.24 0.91
Domain 74 21.22 1.25 31 21.08 1.16 24 21.06 1.25 7 20.70 1.46 12 22.18 1.00
Composite score 80 20.91 0.85 32 20.75 0.76 25 20.80 0.78 8 20.76 1.18 15 21.52 0.74
Abbreviations: ASCT 5 autologous stem cell transplantation; BBBD 5 blood–brain barrier disruption; CHT 5 chemotherapy; f/b 5 followed by; HDCHT 5
high-dose chemotherapy; HDMTX 5 high-dose methotrexate; HVLT-R 5 Hopkins Verbal Learning Test–Revised; IA 5 intra-arterial; WBRT 5 whole-brain
radiotherapy.
a Raw test scores were converted to z scores based on normative values demographically adjusted to age. A z score is the number of SDs above or below
the mean for a population of similar age.
b For each cognitive domain, a domain score was obtained by averaging all test z scores in each domain for each participant.
c A composite score was the average z score calculated by averaging all available domain scores for each participant.
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large number of PCNSL survivors in complete remis-
sion, with a long median follow-up of 5.5 years
(2–26 years). We cannot rule out selection bias and
cannot conclude that the 80 patients are representative
of all long-term PCNSL survivors. Nevertheless,
PCNSL is a rare disease; our study was a multinational
collaborative effort to obtain information on as many
long-term survivors as feasible. Overall, 19% of the
survivors showed impairment in multiple cognitive
domains, including 47% of those treated with WBRT.
This group had poorer attention/executive function,
motor skills, and composite scores than patients not
treated with WBRT. These results are similar to those
reported by others.8,30,31 Five of the 15 participants
treated with WBRT had also received high-dose che-
motherapy and ASCT. It is possible that the combined
treatment further affected neuropsychological out-
comes in the 5 survivors, compared with the 10 who
were not treated with high-dose chemotherapy and
ASCT.32 In our study, the median radiation dose was
45 Gy. Reduced doses of WBRT (23.4 Gy) after com-
plete remission to methotrexate-based chemotherapy
have resulted in disease control.33 Follow-up of a small
number of patients indicates no significant cognitive
decline up to 24 months after reduced-dose WBRT;
however, difficulties in verbal memory andmotor speed
have persisted during ongoing follow-up.34 In our
Figure 1 Neuropsychological outcomes according to treatment group (A) and percentage of survivors with neuropsychological impairment (B)
according to treatment group
(A) Long-term neuropsychological domain (attention/executive function, verbal memory, and motor skills) and neuropsychological composite z score results
(crudemean and SD) are shown. A z score is the number of SDs above or below themean for a population of similar age. *Statistically significant difference (p
# 0.05) between the WBRT group and the non-WBRT groups in attention/executive function, motor skills, and composite score. (B) Percentage of survivors
with neuropsychological impairment according to treatment group. Percentage of survivors by number of cognitive domains impaired at long-term follow-up:
no domains impaired (blue), one domain impaired (green), or multiple ($2) domains impaired (red) according to treatment group. Abbreviations: ASCT 5
autologous stem cell transplantation; BBBD 5 blood–brain barrier disruption; Exec 5 executive; HDMTX 5 high-dose methotrexate; HDT 5 high-dose
chemotherapy; IA 5 intra-arterial; WBRT 5 whole-brain radiotherapy.
Figure 2 Neuroimaging abnormalities according to treatment group
Long-term neuroimaging outcomes, measured by MRI (total T2, n 5 76) or CT (total low
density, n 5 2) areas of abnormalities, in square millimeters (crude mean and SD) according
to treatment group. *Statistically significant difference between the WBRT group and the
non-WBRT groups (p 5 0.0006). Abbreviations: ASCT 5 autologous stem cell transplanta-
tion; BBBD5 blood–brain barrier disruption; HDMTX5 high-dose methotrexate; HDT5 high-
dose chemotherapy; IA 5 intra-arterial; WBRT 5 whole-brain radiotherapy.
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report, there were no differences among the 3 non-
WBRT groups in any outcome measure. Of interest,
8 (12%) of 65 survivors treated with chemotherapy
without WBRT showed cognitive impairment in mul-
tiple domains even after complete disease remission.11
Verbal memory and composite scores improved as
the length of the interval from diagnosis to long-term
evaluation increased. This finding is of significant
interest and may have important implications regard-
ing prognosis. Although “improvement over time”
can be proven only by serial follow-up, the findings
suggest that verbal memory may improve as disease-
free survival increases. Further longitudinal studies of
late treatment effects are needed to corroborate this
finding.
More MR or CT white matter abnormalities were
associated withWBRT and corresponded with poorer
performance in attention/executive function, verbal
memory, and motor skills, and poorer self-perceived
QOL. Our results support studies showing more
treatment-related abnormalities in patients treated
with WBRT and studies reporting an association
between imaging abnormalities and neuropsycholog-
ical scores.6,8,17 In contrast to other PCNSL reports,
the total area of white matter changes did not corre-
late with age or with interval from diagnosis to long-
term evaluation.8,11 Future investigations using MR
diffusion tensor imaging in combination with cogni-
tive assessment may provide a more sensitive measure
of long-term neurotoxic treatment effects, as previ-
ously described.35
Study limitations include the small number of sur-
vivors in the WBRT group and in the high-dose che-
motherapy and ASCT group, which reduces the
study’s power. The difference in numbers of survivors
in the 4 groups is related to different PCNSL treat-
ment studies and regimens offered at the 4 respective
institutions. For example, only 19% were treated
with WBRT. Differences in group sizes may also
reflect increased rates of survivors in complete remis-
sion 2 years after diagnosis who were available to
participate.
Additional study limitations include lack of pre-
and posttreatment baseline neurocognitive evaluations
with the identical test battery on most of the survivors.
Although we attempted to obtain pretreatment MRIs
on all patients, this was not feasible. However, baseline
cognitive data and pretreatment scans are available on
one of the groups (BBBD; N.D. Doolittle and E.A.
Neuwelt, unpublished, 2013). Consequently, our
analysis focused on follow-up data and could not eval-
uate change over time, and survivors were evaluated at
different time points since completing therapy. Still,
the data were very long-term, and to our knowledge
Figure 3 Quality of life outcomes according to treatment group
Long-term quality-of-life results measured by the EORTC QLQ-C30 Functional Scales (crude mean and SD) according to
treatment group. Scores range from 1 to 100. Higher scores represent a higher level of functioning. *Statistically significant
difference between the WBRT group and the non-WBRT groups in the respective functional scale. Abbreviations: ASCT 5
autologous stem cell transplantation; BBBD 5 blood–brain barrier disruption; EORTC QLQ-C30 5 European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire–30; HDMTX 5 high-dose methotrexate; HDT 5 high-
dose chemotherapy; IA 5 intra-arterial; QoL 5 quality of life; WBRT 5 whole-brain radiotherapy.
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this is the longest reported follow-up in PCNSL, pro-
viding unique information for clinicians managing this
rare disease. Another limitation common to observa-
tional studies is that treatment was not randomly as-
signed, and differences in baseline characteristics
could confound comparison results among groups.
Differences in median age across treatments, a possible
confounder, may be partially explained by the fact that
WBRT is often avoided in patients older than 60 years
because of an increased risk of dementia in this age
group.30 However, important baseline characteristics
were measured, and we used a regression model to
control for potential confounding when comparing
treatment groups. Also, neuropsychologists were not
blinded with regard to treatment, and neuropsycholog-
ical tests were standardized using US data because
more localized standard data were not available.
The PCNSL test battery allowed standardized col-
lection of cognitive, QOL, and neuroimaging data
among several international centers. We hope the
findings are valuable as a comparison series of long-
term survivorship for future PCNSL studies, with
the goal to reduce treatment-related neurotoxicity.
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